COLLPLANT BIOTECHNOLOGIES LT (CLGN) Fundamental Analysis & Valuation

NASDAQ:CLGN • IL0004960188

Current stock price

0.339 USD
-0.02 (-5.57%)
Last:

This CLGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CLGN Profitability Analysis

1.1 Basic Checks

  • In the past year CLGN has reported negative net income.
  • CLGN had a negative operating cash flow in the past year.
  • In the past 5 years CLGN reported 4 times negative net income.
  • CLGN had negative operating cash flow in 4 of the past 5 years.
CLGN Yearly Net Income VS EBIT VS OCF VS FCFCLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

  • CLGN's Return On Assets of -86.31% is on the low side compared to the rest of the industry. CLGN is outperformed by 71.57% of its industry peers.
  • CLGN has a Return On Equity of -130.68%. This is in the lower half of the industry: CLGN underperforms 61.12% of its industry peers.
Industry RankSector Rank
ROA -86.31%
ROE -130.68%
ROIC N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
CLGN Yearly ROA, ROE, ROICCLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

  • With a decent Gross Margin value of 63.03%, CLGN is doing good in the industry, outperforming 77.56% of the companies in the same industry.
  • CLGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLGN Yearly Profit, Operating, Gross MarginsCLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CLGN Health Analysis

2.1 Basic Checks

  • CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLGN Yearly Shares OutstandingCLGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CLGN Yearly Total Debt VS Total AssetsCLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -13.62, we must say that CLGN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -13.62, CLGN is doing worse than 79.11% of the companies in the same industry.
  • CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.62
ROIC/WACCN/A
WACC8.53%
CLGN Yearly LT Debt VS Equity VS FCFCLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • CLGN has a Current Ratio of 3.66. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
  • CLGN's Current ratio of 3.66 is in line compared to the rest of the industry. CLGN outperforms 44.87% of its industry peers.
  • A Quick Ratio of 3.45 indicates that CLGN has no problem at all paying its short term obligations.
  • The Quick ratio of CLGN (3.45) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.66
Quick Ratio 3.45
CLGN Yearly Current Assets VS Current LiabilitesCLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CLGN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 35.62% over the past year.
EPS 1Y (TTM)35.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-63.41%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.27% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 42.44% on average over the next years. This is a very strong growth
EPS Next Y54.97%
EPS Next 2Y40.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-7.59%
Revenue Next 2Y12.94%
Revenue Next 3Y42.44%
Revenue Next 5YN/A

3.3 Evolution

CLGN Yearly Revenue VS EstimatesCLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M 20M 25M
CLGN Yearly EPS VS EstimatesCLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. CLGN Valuation Analysis

4.1 Price/Earnings Ratio

  • CLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLGN Price Earnings VS Forward Price EarningsCLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLGN Per share dataCLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CLGN's earnings are expected to grow with 40.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.27%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLGN Dividend Analysis

5.1 Amount

  • CLGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLGN Fundamentals: All Metrics, Ratios and Statistics

COLLPLANT BIOTECHNOLOGIES LT

NASDAQ:CLGN (4/8/2026, 8:23:50 PM)

0.339

-0.02 (-5.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-26
Inst Owners14.75%
Inst Owner Change0%
Ins Owners29.81%
Ins Owner Change0%
Market Cap4.33M
Revenue(TTM)N/A
Net Income(TTM)-12.16M
Analysts80
Price Target11.22 (3209.73%)
Short Float %0.76%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-183.43%
Min EPS beat(2)-270.78%
Max EPS beat(2)-96.08%
EPS beat(4)0
Avg EPS beat(4)-151.67%
Min EPS beat(4)-270.78%
Max EPS beat(4)-21.21%
EPS beat(8)0
Avg EPS beat(8)-113.94%
EPS beat(12)1
Avg EPS beat(12)164.56%
EPS beat(16)1
Avg EPS beat(16)88.54%
Revenue beat(2)0
Avg Revenue beat(2)-95.77%
Min Revenue beat(2)-98.44%
Max Revenue beat(2)-93.1%
Revenue beat(4)0
Avg Revenue beat(4)-69.54%
Min Revenue beat(4)-98.44%
Max Revenue beat(4)-23.83%
Revenue beat(8)0
Avg Revenue beat(8)-74.59%
Revenue beat(12)3
Avg Revenue beat(12)-42.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-58.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-71.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.75
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.19
BVpS0.73
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -86.31%
ROE -130.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.03%
FCFM N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.68%
Cap/Sales 2.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.66
Quick Ratio 3.45
Altman-Z -13.62
F-Score4
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)85.11%
Cap/Depr(5y)108.12%
Cap/Sales(3y)180.83%
Cap/Sales(5y)112.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y54.97%
EPS Next 2Y40.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-63.41%
Revenue Next Year-7.59%
Revenue Next 2Y12.94%
Revenue Next 3Y42.44%
Revenue Next 5YN/A
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-108.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-164.01%
OCF growth 3YN/A
OCF growth 5YN/A

COLLPLANT BIOTECHNOLOGIES LT / CLGN Fundamental Analysis FAQ

What is the fundamental rating for CLGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to CLGN.


What is the valuation status for CLGN stock?

ChartMill assigns a valuation rating of 1 / 10 to COLLPLANT BIOTECHNOLOGIES LT (CLGN). This can be considered as Overvalued.


What is the profitability of CLGN stock?

COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a profitability rating of 1 / 10.


Can you provide the financial health for CLGN stock?

The financial health rating of COLLPLANT BIOTECHNOLOGIES LT (CLGN) is 6 / 10.